Cover Image
市場調查報告書

Spectrum Pharmaceuticals, Inc.:產品平台分析

Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240939
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
Spectrum Pharmaceuticals, Inc.:產品平台分析 Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 81 Pages
簡介

Spectrum Pharmaceuticals, Inc.(前 NeoTherapeutics, Inc.)為生物科技企業,以血液學及腫瘤學為焦點,致力於後期臨床試驗及市售商品產品的獲得、開發及商品化。

本報告提供Spectrum Pharmaceuticals, Inc.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的,作用機制,給藥途徑,分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Spectrum Pharmaceuticals, Inc.的基本資料

Spectrum Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Spectrum Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Spectrum Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Spectrum Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Spectrum Pharmaceuticals, Inc.:藥物簡介

  • apaziquone
  • vincristine sulfate
  • eflapegrastim
  • belinostat
  • menadione sodium bisulfite
  • ozarelix
  • poziotinib
  • pralatrexate
  • SPI-014
  • SPI-1620
  • Alocrest
  • MTRN-2696
  • SPI-205
  • topotecan hydrochloride
  • melphalan
  • Yttritum 90 ibritumomab tiuxetan

Spectrum Pharmaceuticals, Inc.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Spectrum Pharmaceuticals, Inc.:最近的開發平台趨勢

Spectrum Pharmaceuticals, Inc.:暫停中的計劃

Spectrum Pharmaceuticals, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • efaproxiral
    • ortataxel
    • RH-1

Spectrum Pharmaceuticals, Inc.:企業發表

Spectrum Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08029CDB

Summary

Global Markets Direct's, 'Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Spectrum Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Spectrum Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Spectrum Pharmaceuticals, Inc.
  • The report provides overview of Spectrum Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Spectrum Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Spectrum Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Spectrum Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Spectrum Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Spectrum Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Spectrum Pharmaceuticals, Inc. Snapshot
    • Spectrum Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Spectrum Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Spectrum Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Spectrum Pharmaceuticals, Inc. - Pipeline Products Glance
    • Spectrum Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Spectrum Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Spectrum Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Spectrum Pharmaceuticals, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Spectrum Pharmaceuticals, Inc. - Drug Profiles
    • apaziquone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eflapegrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • belinostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • menadione sodium bisulfite
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozarelix
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • poziotinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pralatrexate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-014
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-1620
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alocrest
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTRN-2696
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-205
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • topotecan hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • melphalan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Yttritum 90 ibritumomab tiuxetan
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Spectrum Pharmaceuticals, Inc. - Pipeline Analysis
    • Spectrum Pharmaceuticals, Inc. - Pipeline Products by Target
    • Spectrum Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Spectrum Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Spectrum Pharmaceuticals, Inc. - Dormant Projects
  • Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • efaproxiral
      • ortataxel
      • RH-1
  • Spectrum Pharmaceuticals, Inc. - Company Statement
  • Spectrum Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Spectrum Pharmaceuticals, Inc., Key Information
  • Spectrum Pharmaceuticals, Inc., Key Facts
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Spectrum Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Spectrum Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Spectrum Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Spectrum Pharmaceuticals, Inc. - Pre-Registration, 2016
  • Spectrum Pharmaceuticals, Inc. - Phase III, 2016
  • Spectrum Pharmaceuticals, Inc. - Phase II, 2016
  • Spectrum Pharmaceuticals, Inc. - Phase I, 2016
  • Spectrum Pharmaceuticals, Inc. - Preclinical, 2016
  • Spectrum Pharmaceuticals, Inc. - Unknown, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Spectrum Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Spectrum Pharmaceuticals, Inc., Other Locations
  • Spectrum Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Spectrum Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Spectrum Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Spectrum Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Spectrum Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top